Clinuvel Pharmaceuticals Ltd. launched Scenesse (afamelanotide) in Europe in 2016 and now the company is preparing a similar commercialization and pricing strategy for the ultra-orphan drug in the US. The company has submitted a rolling NDA to the FDA for Scenesse for patients with erythropoietic protoporphyria (EPP), an ultra-rare condition that causes severe reactions to light, or phototoxicity.
The company, based in Melbourne Australia, announced the rolling new drug application (NDA) submission in June, but on Sept. 5...






